Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions: ReCharge, TakeCharge; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetic Macular Edema
Interventions: triamcinolone acetonide; Drug
Lead sponsor: SurModics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 4
States / cities: Phoenix, Arizona • Santa Barbara, California • Detroit, Michigan + 1 more

Conditions: Healthy
Interventions: Fasting, non fasting; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Schizophrenia
Interventions: Ziprasidone; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Cabotegravir 30 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Healthy
Interventions: amoxicillin 400mg + clovalunic acid 57.5mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Gestational Diabetes
Interventions: Mobile health app called "Hola Bebe"; Behavioral
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Colorectal Cancer
Interventions: Standard Inspection Colonoscopy, Dual Inspection Colonoscopy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Nisoldipine Extended-release Tablets, 30 mg, Sular® Extended Release Tablets, 30 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV Infections
Interventions: HIV test by oral swab; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Insulin Resistance
Interventions: SFA diet, MUFA diet, CARB diet; Other
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 40 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Lung Biopsy, Lung Cancer, Lung Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: Invenio Imaging Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: San Diego, California • Jacksonville, Florida • Grand Rapids, Michigan + 4 more

Conditions: DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions: Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 40 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Liver Diseases, Healthy
Interventions: Zongertinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Human Gastrointestinal Physiology Data
Interventions: Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans; Drug · Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Spinal Cord Injury
Interventions: 2 hour Oral Glucose Tolerance Test, Fat Meal Test; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Healthy Volunteers
Interventions: Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions: Metformin, Insulin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 26
States / cities: Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Type II Diabetes Mellitus
Interventions: CX11, Placebo; Drug · Other
Lead sponsor: Corxel Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 24 more

Conditions: Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions: Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 16 Years to 35 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART

Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema

Intermittent Fasting on Body Fat and Quality of Life

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Linagliptin Inpatient Trial

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions

Mobile Health App to Reduce Diabetes in Latina Women

A Comparison of Methods to Detect Polyps During Colonoscopy

Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions

Rapid HIV Testing Program in the Emergency Department

Dietary Lipid Induced Insulin Resistance

A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study

Natural History Study for DNA Repair Disorders

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment

Cardiovascular Disease Study

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

Minnesota Community-Based Cognitive Training in Early Psychosis